Overview: MAG-SGPG IgM TestIntroduction: The MAG-SGPG IgM Test detects MAG-SGPG IgM antibodies to diagnose peripheral neuropathy, causing tingling or muscle weakness. Following 2023 AAN guidelines, it uses immunoassay for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected MAG-associated neuropathy or related disorders.
Other Names: MAG-SGPG IgM Assay, Neuropathy IgM Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: MAG-SGPG IgM testing began in the 1990s with neuropathy research. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects MAG-SGPG IgM antibodies to diagnose peripheral neuropathy, guides treatment, and evaluates patients with tingling or muscle weakness.
Test Parameters: 1. MAG-SGPG IgM Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of tingling, muscle weakness, or neuropathic symptoms.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document tingling, muscle weakness, numbness, or history of autoimmune diseases. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, neuropathy implications, and risks of sample collection.
Procedural Considerations: Uses immunoassay to detect MAG-SGPG IgM antibodies in serum or saliva. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for neuropathy diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Insufficient sample volume may reduce accuracy.
Clinical Significance: Positive MAG-SGPG IgM confirms peripheral neuropathy, guiding immunosuppressive therapy (e.g., rituximab). Negative results may require further neuropathy testing.
Specialist Consultation: Consult a neurologist for result interpretation and treatment planning.
Additional Supporting Tests: Nerve conduction studies, anti-MAG IgM, or nerve biopsy to confirm neuropathy diagnosis.
Test Limitations: Not all neuropathies are MAG-SGPG-associated; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Neuropathy Guidelines, 2023; Neurology, Latov N, 2022.
